Healthcare utilization and costs following newly diagnosed type-2 diabetes in Sweden: A follow-up of 38,956 patients in a clinical practice setting

Impact of a general practitioner-led integrated model of care on the cost of potentially preventable diabetes-related hospitalisations

“…Leveraging the quality and efficiency benefits of better integrated care is now a national priority for governments, consumers, and health care providers [13]. Integrated primary- secondary care can reduce both the number and associated cost of PPH-D whilst preserving care quality [9,14]. If these savings from PPH-D are extrapolated to all similar hospitalisations in Australia then the savings are in the realm of AUD$132.5 million annually.…”

Weight change patterns and healthcare costs in patients with newly-diagnosed type-2 diabetes in Sweden

“…Data for this study were collected from 84 primary-care centers in Sweden between 1999 and 2009 and extracted from the ROSE (Retrospective Epidemiological Study to Investigate Outcome and Mortality with Glucose-lowering Drug Treatment in Primary Care) study [14]. The index date of diagnosis was defined by the diagnostic code in the registry data or the first prescription of a blood glucose-lowering drug.…”

Increased healthcare utilization costs following initiation of insulin treatment in type 2 diabetes: A long-term follow-up in clinical practice

“…A total of 58 333 patients could be included, and data linked to the Swedish National Patient-, Prescribed Drug-and Cause of Death registries by using the unique personal identification number, mandatory for all citizens from birth or immigration. Details on study design and the data extraction from primary care records and registers have been described elsewhere [2,4,8,22,32].…”

“…Costs of pharmaceuticals and devices of glucose monitoring are excluded from this study because prescription data were not available for the full study period. More details on the cost assessment have been described previously [22].…”

“…Furthermore, recent studies report associations between insulin and increased risk of cancer, cardiovascular disease and all-cause mortality [18][19][20]. Thus, despite the low direct cost of insulin treatment, unwanted side effects and treatment complexity of insulin may lead to increased long-term health care costs [21][22][23]. Despite several studies on health care costs and T2DM [24][25][26][27][28][29][30] there are limited data on use of health care resource associated with insulin.…”